{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:56:37Z","timestamp":1791176197028,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":165,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.jhep.2012.09.023","type":"journal-article","created":{"date-parts":[[2012,10,9]],"date-time":"2012-10-09T02:31:12Z","timestamp":1349749872000},"page":"391-394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Triple therapy with first generation HCV protease inhibitors: Lead-in or no lead-in phase?"],"prefix":"10.1016","volume":"58","author":[{"given":"Alina","family":"Pascale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Serfaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2012.09.023_b0005","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"Management of hepatitis C virus infection","volume":"55","author":"EASL Clinical Practice Guidelines","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.09.023_b0010","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2012.09.023_b0015","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2012.09.023_b0020","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2012.09.023_b0025","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2012.09.023_b0030","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial","volume":"376","author":"Kwo","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2012.09.023_b0035","first-page":"A931","article-title":"Efficacy of boceprevir in prior null responders to peg-interferon\u2013ribavirin: the PROVIDE study","volume":"54","author":"Vierling","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.09.023_b0080","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2012.05.011","article-title":"Factors that predict response of patients with HCV infection to boceprevir","volume":"143","author":"Poordad","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2012.09.023_b0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2009.10.003","article-title":"Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis","volume":"52","author":"Moreno","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.09.023_b0085","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","article-title":"Interleukin-28B Polymorphism Improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus","volume":"139","author":"Thomson","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2012.09.023_b0090","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/j.1478-3231.2012.02856.x","article-title":"Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver","volume":"32","author":"Leroy","year":"2012","journal-title":"Liver Intern"},{"key":"10.1016\/j.jhep.2012.09.023_b0095","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/hep.25734","article-title":"Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype1 chronic hepatitis C","volume":"56","author":"Camma","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.09.023_b0065","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/S0168-8278(12)61106-4","article-title":"100% SVR in IL28B CC patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the Prove2 trial","volume":"56","author":"Bronowicki","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.09.023_b0070","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(12)60022-1","article-title":"Safety of telaprevir or boceprevir in combination with peginterferon alfa\/ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS CO20-CUPIC)","volume":"56","author":"H\u00e9zode","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.09.023_b0075","doi-asserted-by":"crossref","first-page":"S549","DOI":"10.1016\/S0168-8278(12)61410-X","article-title":"A randomized trial comparing ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon\/ribavirin","volume":"56","author":"Poordad","year":"2012","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827812007544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827812007544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:10:42Z","timestamp":1781111442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827812007544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0168827812007544"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2012.09.023","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triple therapy with first generation HCV protease inhibitors: Lead-in or no lead-in phase?","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2012.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}